JP2020523331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523331A5 JP2020523331A5 JP2019568054A JP2019568054A JP2020523331A5 JP 2020523331 A5 JP2020523331 A5 JP 2020523331A5 JP 2019568054 A JP2019568054 A JP 2019568054A JP 2019568054 A JP2019568054 A JP 2019568054A JP 2020523331 A5 JP2020523331 A5 JP 2020523331A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- substituted
- substituents selected
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- -1 pyridadinyl Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517204P | 2017-06-09 | 2017-06-09 | |
| US62/517,204 | 2017-06-09 | ||
| PCT/US2018/036627 WO2018227061A1 (en) | 2017-06-09 | 2018-06-08 | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523331A JP2020523331A (ja) | 2020-08-06 |
| JP2020523331A5 true JP2020523331A5 (enExample) | 2021-07-26 |
| JP7088965B2 JP7088965B2 (ja) | 2022-06-21 |
Family
ID=62751597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568054A Active JP7088965B2 (ja) | 2017-06-09 | 2018-06-08 | アリール複素環ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11124494B2 (enExample) |
| EP (1) | EP3634956B1 (enExample) |
| JP (1) | JP7088965B2 (enExample) |
| KR (1) | KR102615099B1 (enExample) |
| CN (1) | CN110997653B (enExample) |
| ES (1) | ES2874352T3 (enExample) |
| WO (1) | WO2018227061A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6811241B2 (ja) | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227058A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EA202092094A1 (ru) | 2018-03-05 | 2020-12-10 | Бристол-Маерс Сквибб Компани | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| SG11202110742TA (en) | 2019-04-02 | 2021-10-28 | Aligos Therapeutics Inc | Compounds targeting prmt5 |
| EP4196471A1 (en) * | 2020-08-12 | 2023-06-21 | Bristol-Myers Squibb Company | Oxopyrrolidine urea fpr2 agonists |
| WO2024220487A1 (en) * | 2023-04-18 | 2024-10-24 | Bristol-Myers Squibb Company | Carbocyclic phenylpyrrolidinone urea fpr2 agonists |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7678913B2 (en) * | 2004-12-07 | 2010-03-16 | Portola Pharmaceuticals, Inc. | Ureas as factor Xa inhibitors |
| RS57036B1 (sr) | 2013-11-28 | 2018-05-31 | Kyorin Pharmaceutical Co Ltd | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom 1 (fprl-1) |
| CN107848962B (zh) | 2015-05-27 | 2021-04-09 | 杏林制药株式会社 | 脲衍生物或其药理学上可接受的盐 |
| ES2814126T3 (es) | 2015-05-27 | 2021-03-26 | Kyorin Seiyaku Kk | Derivado de urea o sal farmacológicamente aceptable del mismo |
| MX2018005756A (es) | 2015-11-24 | 2018-08-01 | Squibb Bristol Myers Co | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
| JP6811241B2 (ja) * | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227058A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EA202092094A1 (ru) | 2018-03-05 | 2020-12-10 | Бристол-Маерс Сквибб Компани | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 |
-
2018
- 2018-06-08 JP JP2019568054A patent/JP7088965B2/ja active Active
- 2018-06-08 EP EP18734731.5A patent/EP3634956B1/en active Active
- 2018-06-08 CN CN201880050608.1A patent/CN110997653B/zh active Active
- 2018-06-08 ES ES18734731T patent/ES2874352T3/es active Active
- 2018-06-08 US US16/619,965 patent/US11124494B2/en active Active
- 2018-06-08 KR KR1020207000305A patent/KR102615099B1/ko active Active
- 2018-06-08 WO PCT/US2018/036627 patent/WO2018227061A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523331A5 (enExample) | ||
| JP2021516240A5 (enExample) | ||
| IL277044B1 (en) | Phenylpyrrolidinone formyl peptide 2 receptor agonists | |
| JP2020523332A5 (enExample) | ||
| AU2014233414B2 (en) | N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2018516904A5 (enExample) | ||
| JP2016519165A5 (enExample) | ||
| MX2019002212A (es) | Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos. | |
| RU2016123449A (ru) | Октагидро конденсированные азадекалиновые модуляторы глюкокортикоидного рецептора | |
| MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| JP2016517417A5 (enExample) | ||
| JP2018538248A5 (enExample) | ||
| JP2017512786A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2017537948A5 (enExample) | ||
| PH12019502425A1 (en) | Crystalline forms of a jak inhibitor compound | |
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| BR112018075206A2 (pt) | tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| JP2017501237A5 (enExample) | ||
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| JP2014510147A5 (enExample) | ||
| MY200531A (en) | 2,6-diamino pyridine compounds | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| JP2018501215A5 (enExample) | ||
| JP2020523327A5 (enExample) |